Stock CRVO CERVOMED INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News CervoMed Inc.

Equities

CRVO

US15713L1098

Real-time Estimate Cboe BZX
Other stock markets
 02:18:47 2024-05-28 pm EDT 		5-day change 1st Jan Change
18.47 USD -1.18% Intraday chart for CervoMed Inc. -5.86% +139.84%
May. 20 CervoMed Names William Elder CFO MT
May. 15 Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CervoMed Names William Elder CFO
MT
CervoMed to Appoint William Elder as Chief Financial Officer
AQ
Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M
MT
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
AQ
CervoMed : Nominating and Corporate Governance Committee Charter
PU
CervoMed : Corporate Presentation April 2024
PU
Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating
MT
CervoMed : Corporate Presentation April 2024
PU
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
AQ
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CervoMed to Participate in Upcoming Investor Conferences
AQ
CervoMed Prices $50 Million Equity Sale to Private Investors
MT
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
AQ
CervoMed Inc. announced that it expects to receive $49.999967 million in funding
CI
CervoMed : Shareholder Meeting - Form 8-K
PU
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
AQ
CervoMed to Participate in the BIO CEO and Investor Conference
AQ
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
AQ
Canaccord Genuity Starts CervoMed With Buy Rating, $50 Price Target
MT
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRVO Stock
  4. News CervoMed Inc.